DelveInsight’s, “Bipolar Disorder Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Bipolar Disorder pipeline landscape. It covers the Bipolar Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Bipolar Disorder Pipeline Report
- DelveInsight’s Bipolar Disorder pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Bipolar Disorder treatment.
- The leading companies working in the Bipolar Disorder Market include Vanda Pharmaceuticals, Reviva Pharmaceuticals, SK BIOPHARMACEUTICALS, Pear Therapeutics, Arvelle Therapeutics, Janssen Research & Development, Sunovion Pharmaceuticals, Lyndra Therapeutics, ILTOO Pharma, COMPASS Pathways, NRx Pharmaceuticals, Carlsson Research AB, Sunovion, SAGE Therapeutics, Alzamend Neuro, OWP Pharmaceuticals, Entheogenix Biosciences, and others.
- Promising Bipolar Disorder Pipeline Therapies in the various stages of development include Risperdal Consta, Seroquel IR 300mg, Quetiapine Formulation A 300mg, Sublingual film containing Dexmedetomidine (BXCL501), and others.
- September 2023: Janssen Pharmaceutical N.V., Belgium announced a study of phase 2 clinical trials for JNJ-55308942. The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
- September 2023: BioXcel Therapeutics Inc. announced a study of phase 3 clinical trials for Sublingual film containing Dexmedetomidine (BXCL501). This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.
Request a sample and discover the recent advances in Bipolar Disorder Treatment Drugs @ Bipolar Disorder Pipeline Report
In the Bipolar Disorder pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Bipolar Disorder clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Bipolar Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Bipolar Disorder Overview
Bipolar disorder is a brain disorder that causes changes in a person’s mood, energy, and ability to function. People with bipolar disorder experience intense emotional states that typically occur during distinct periods of days to weeks, called mood episodes. These mood episodes are categorized as manic/hypomanic (abnormally happy or irritable mood) or depressive (sad mood).
Find out more about Bipolar Disorder Therapeutics Assessment @ Bipolar Disorder Preclinical and Discovery Stage Products
Bipolar Disorder Emerging Drugs Profile
- Iloperidone: Vanda Pharmaceuticals
- RP5063: Reviva Pharmaceuticals
Bipolar Disorder Pipeline Therapeutics Assessment
There are approx. 22+ key companies which are developing the Bipolar Disorder therapies. The Bipolar Disorder companies which have their Bipolar Disorder drug candidates in the most advanced stage, i.e. phase III include, Vanda Pharmaceuticals.
Learn more about the emerging Bipolar Disorder Pipeline Therapies @ Bipolar Disorder Clinical Trials Assessment
Scope of the Bipolar Disorder Pipeline Report
- Coverage- Global
- Bipolar Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Bipolar Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Bipolar Disorder Companies- Vanda Pharmaceuticals, Reviva Pharmaceuticals, SK BIOPHARMACEUTICALS, Pear Therapeutics, Arvelle Therapeutics, Janssen Research & Development, Sunovion Pharmaceuticals, Lyndra Therapeutics, ILTOO Pharma, COMPASS Pathways, NRx Pharmaceuticals, Carlsson Research AB, Sunovion, SAGE Therapeutics, Alzamend Neuro, OWP Pharmaceuticals, Entheogenix Biosciences, and others.
- Bipolar Disorder Pipeline Therapies- Risperdal Consta, Seroquel IR 300mg, Quetiapine Formulation A 300mg, Sublingual film containing Dexmedetomidine (BXCL501), and others.
Dive deep into rich insights for new drugs for Bipolar Disorder treatment, Visit @ Bipolar Disorder Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Bipolar Disorder: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Bipolar Disorder – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Iloperidone: Vanda Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- OSU6162: Carlsson Research AB
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RP5063: Reviva Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Research programme: small molecule therapeutics: Entheogenix Biosciences
- Drug profiles in the detailed report…..
- Inactive Products
- Bipolar Disorder Key Companies
- Bipolar Disorder Key Products
- Bipolar Disorder- Unmet Needs
- Bipolar Disorder- Market Drivers and Barriers
- Bipolar Disorder- Future Perspectives and Conclusion
- Bipolar Disorder Analyst Views
- Bipolar Disorder Key Companies
- Appendix
For further information on the Bipolar Disorder Pipeline therapeutics, reach out to Bipolar Disorder Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking